Heart Failure
Pipeline by Development Stage
Drug Modality Breakdown
Heart Failure is a ~$56M Medicare Part D market dominated by a single blockbuster (CORLANOR) approaching loss of exclusivity in 2027.
Key Trends
- Ivabradine (CORLANOR) accounts for 84% of market value; patent cliff imminent in June 2027
- Diuretics and aldosterone antagonists remain foundational but commoditized; limited pricing power
- High clinical trial volume (1,618 trials) signals ongoing innovation in background, but few products reaching market
Career Verdict
Attractive for specialists willing to bet on pipeline depth and post-LOE consolidation, but risky if joining only to defend legacy franchises.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | CORLANOR (ivabradine) | Amgen | $47M | 84% | LOE_APPROACHING | Declining | 1.0yr |
| 2 | SOAANZ (torsemide) | PharmaIN | $5M | 9% | PEAK | Stable | |
| 3 | BIDIL (hydralazine/isosorbide dinitrate) | R-Pharm US | $2M | 4% | LOE_APPROACHING | Stable |
Drug Class Breakdown
facing patent cliff 2027
stable; commoditized
mature; generic competition
niche; limited adoption
Career Outlook
StableHeart Failure is a stable, mature market facing a near-term disruption: loss of CORLANOR exclusivity in June 2027 will reshape competitive positioning and likely trigger consolidation. Commercial acumen and digital patient engagement will be highly valued in the post-patent-cliff era, while pipeline-focused roles remain at risk if late-stage assets do not advance. Specialists entering now should expect 2–3 years of stability followed by strategic repositioning.
Breaking In
Join a company with robust pipeline assets (e.g., AstraZeneca, J&J) or a commercial specialist firm (e.g., Abbott diagnostics) to gain exposure to both innovation and commercialization; avoid pure-play defenders of aging franchises.
For Experienced Professionals
Pivot toward HF phenotyping, digital biomarkers, or HFpEF opportunities where innovation is still early; the HFrEF space is commoditizing fast, and expertise in emerging segments will command premium valuations.
In-Demand Skills
Best For
Hiring Landscape
Heart Failure hiring is concentrated in commercial roles (1,844 jobs, $255K avg) and engineering (900 jobs, $2.375M avg), reflecting post-LOE genericization and digital health investment. Abbott and Johnson & Johnson are top external recruiters for HF talent, though internal pharma hiring within HF-focused companies (Amgen, AstraZeneca) is moderate. Salary compression in R&D ($222K) versus engineering suggests technical roles command premium pay.
By Department
Strong demand in commercial and digital health roles, but watch for compression post-CORLANOR LOE; clinical operations roles remain well-compensated.
On Market (8)
Approved therapies currently available
Competitive Landscape
135 companies ranked by most advanced pipeline stage
+105 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 17,756 patients across 50 trials
Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania
Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure
The STOP-MED CTRCD Trial
Impact of Vericiguat on Hemodynamics of Heart Failure
The Fontan Dapagliflozin Pilot Study
COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure
The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation
Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM)
Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands
Effect of Levosimendan or Placebo on Exercise in Advanced Chronic Heart Failure
The Study of Qishenyiqi Drop Pills in Improving the Prognosis of Heart Failure Patients
The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients
DANHEART (H-HeFT and Met-HeFT)
Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients
LINQ for impEdance meAsuremeNt While Off From HF Medication Study
Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction
Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Aquaresis Utility for Hyponatremic Acute Heart Failure Study
Quadripolar Leads for the Management of Heart Failure Patients in the Middle East
123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging on a Small Field of View-High Efficiency Cardiac SPECT System
Monitoring of Hemodynamics in Heart Failure Patients by Intracardiac Impedance Measurement
Levosimendan Efficacy Assessment by Cardiopulmonary Exercise Test (CPET)
Substudy on the Mechanistic Plausibility of the Clinical Benefits of Adaptive Servo-ventilation
The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study
Right Ventricular (RV) Pacing in Early Post-operative Continuous Flow Left Ventricular Assist Device (LVAD)
Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients
Resynchronization in Paced Heart Failure Patients With Implantable Cardioverter Defibrillator (ICD) Indication
Preoperative Levosimendan and Heart Failure
Quartet Lead and Resynchronization Therapy Options
Safety and Efficacy of Direct Blood Volume Measurement in the Treatment of Heart Failure
Monitoring of Fluid Status in Heart Failure Patients by Intrathoracic Impedance Measurement in Japan (J-HomeCARE II)
PhrenIc Nerve mappinG and Stimulation EP Catheter Study: PING-EP Study
Clinical Status Monitoring in Implantable Cardiac Defibrillator (ICD) Patients by Physiological Diagnosis (PhD) Function
Multisite Pacing With a Quadripolar Lead
Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction
OptiVol® Care Pathway
Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)
Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome
Cardiac Resynchronization Therapy (CRT)-Narrow-dp/Dt-Study
Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion
Medtronic South Asian Systolic Heart Failure Registry
OptiLink HF Study: Optimization of Heart Failure Management Using Medtronic OptiVol Fluid Status Monitoring and CareLink Network
Monitoring of Fluid Status in Heart Failure Patients by Intrathoracic Impedance Measurement (HomeCARE II)
Comparison of AV Optimization Methods Used in Cardiac Resynchronization Therapy (CRT)
Using Clonidine to Improve Leg Weakness in People With Heart Failure
Optimal Programming to Improve Mechanical Indices, Symptoms and Exercise in Cardiac Resynchronization Therapy.
Flu Vaccination in Congestive Heart Failure
Diagnostic Outcome Trial in Heart Failure (DOT-HF Trial)
Related Jobs in Cardiovascular
Lab Assistant
Director, Franchise Strategic Marketing
Quality Control Analyst II
Quality Control Analyst
Research Associate I
Product Manager, Heart Failure
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.